Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

Summary

The objective of this study is to compare the modulation of pergolide, a D1/D2 receptor agonist, to placebo in non-acute schizophrenic subjects under concomitant therapy with atypical antipsychotics on specific PFC functions. Further aims are to assess the influence of pergolide on psychopathology and extrapyramidal symptoms in comparison to placebo.

Timeline

Start

2003-10

Primary completion

2008-03

Completion

2008-03

Drugs

Indications